The European Medicines Agency (EMA) has granted approval for Dupixent, a therapy developed by Sanofi and Regeneron, to treat eosinophilic esophagitis (EoE) in children as young as one year old. This decision marks a critical step in addressing a condition that has left young patients and their families with limited options. With this approval, Dupixent […]
Sanofi has confirmed its exclusive negotiations with Clayton, Dubilier & Rice (CD&R) for the sale of a 50% stake in its consumer healthcare business, Opella. This deal, valued at around $16.4 billion (€15 billion), is one of Europe’s largest transactions in 2024 and underscores the pharmaceutical giant’s shift toward focusing on innovative medicines and vaccines. […]
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a leader in the biopharmaceutical sector focusing on targeted protein degradation (TPD), has announced a significant expansion of its ongoing Phase 2 clinical trials for KT-474. This decision, influenced by positive preliminary safety and efficacy data reviewed by an Independent Data Review Committee, was communicated by Sanofi, Kymera’s strategic partner. […]
The European Medicines Agency (EMA) has granted approval to Dupixent (dupilumab) as a novel add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by elevated blood eosinophils. This marks the first time Dupixent, jointly developed by Sanofi and Sanofi and Regeneron, is approved for this specific patient group within the European […]
Global pharmaceutical leader Lupin Limited (Lupin) has announced the completion of a strategic acquisition through its European hub, Lupin Atlantis Holdings SA. The company has acquired the well-established brands Aarane and Nalcrom from Sanofi, encompassing operations in Germany, Canada, and the Netherlands. This acquisition includes trademark rights and is set to significantly enhance Lupin’s position […]
Sonofi and Sobi have secured the approval of the US Food and Drug Administration (FDA) for their Altuviiio [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] for hemophilia A treatment. Altuviiio, previously known as efanesoctocog alfa, is a first-in-class, high-sustained factor VIII replacement therapy indicated for routine prophylaxis and on-demand treatment to control bleeding episodes, as well […]
French pharmaceutical company Sanofi and Regeneron, an American biotechnology company, have received the approval of the European Commission (EC) to market their Dupixent (dupilumab) injection in the European Union for eosinophilic esophagitis (EoE). Dupixent is indicated in adults and adolescents 12 years and over, who are not candidates for conventional medicinal treatment. With the approval, […]
Regeneron Pharmaceuticals has secured the approval of the Japanese Ministry of Health, Labor and Welfare (MHLW) to manufacture and market the company’s Libtayo (cemiplimab) for advanced or recurrent cervical cancer. Libtayo is a type of immunotherapy intended for the treatment of patients with advanced or recurrent cervical cancer whose disease progressed after chemotherapy. The approval […]
Chinese biopharma company Innovent Biologics and French pharma giant Sanofi have entered into a partnership that aims to bring innovative drugs to patients in China suffering from difficult-to-treat cancers. The two parties plan to expedite the development and commercialization of a couple of important clinical stage oncology assets of Sanofi, which are SAR408701 (tusamitamab ravtansine; […]
Adagene, a US-based biopharma company, has signed a collaboration and license deal worth up to $2.5 billion plus royalties with Sanofi to produce masked monoclonal and bispecific immuno-oncology antibody candidates for development and commercialization by the latter. As per the terms of the deal, Adagene will handle the early stage research activities for developing masked […]